Reported Saturday, Merus Unveils Clinically Meaningful Activity For Petosemtamab In 2L+ R/M HNSCC And Expands Evaluation In MCRC
Reported Saturday, Merus Unveils Clinically Meaningful Activity For Petosemtamab In 2L+ R/M HNSCC And Expands Evaluation In MCRC
据报告，Merus公布了Petosemtamab在2L+ R/m HNSCC中具有临床意义的活性，并扩大了在MCRC中的评估。
- Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025
- Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025
- Petosemtamab与pembrolizumab联合用于1L复发/转移性PD-L1表达的头颈部鳞状细胞癌，目前正在进行中，计划于2025年更新临床数据。
- Petosemtamab在转移性结直肠癌(mCRC)的评估扩大至包括1L和3L以上；初步临床数据计划于2025年发布。
资讯热榜
更新时间